SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SYRE SPYRE THERAPEUTICS INC

休市中 02-06 16:00:00 EST

35.12

+2.18

+6.62%

盘后35.12

+0.000.00%

18:23 EST

最高35.21	最低33.16	成交量79.05万
今开33.77	昨收32.94	日振幅6.22%
总市值27.25亿	流通市值22.42亿	总股本7,759万
成交额2,717万	换手率1.24%	流通股本6,383万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":35.12,"timestamp":1770411600000,"preClose":32.94,"halted":0,"volume":790541,"hourTrading":{"tag":"盘后","latestPrice":35.12,"preClose":35.12,"latestTime":"18:23 EST","volume":11289,"amount":396468.51,"timestamp":1770420233886,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.06618093503339405,"floatShares":63829799,"shares":77592130,"eps":-2.003614,"marketStatus":"休市中","change":2.18,"latestTime":"02-06 16:00:00 EST","open":33.77,"high":35.21,"low":33.16,"amount":27173236.542983,"amplitude":0.062234,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.003614,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":32.94,"preHourTrading":{"tag":"盘前","latestPrice":33.2602,"preClose":32.94,"latestTime":"08:59 EST","volume":6,"amount":198.93518999999998,"timestamp":1770386391821,"change":0.3202,"changeRate":0.009721,"amplitude":0.004751},"postHourTrading":{"tag":"盘后","latestPrice":35.12,"preClose":35.12,"latestTime":"18:23 EST","volume":11289,"amount":396468.51,"timestamp":1770420233886,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.404608613447325,"impliedVol":0.5293,"impliedVolPercentile":0.3068},"requestUrl":"/m/hq/s/SYRE","defaultTab":"news","newsList":[{"id":"1177535994","title":"Spyre Therapeutics - Spy003显示约85天的半衰期，支持每季度或每年两次的维持剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1177535994","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177535994?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:40","pubTimestamp":1762292412,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics - Spy003显示约85天的半衰期，支持每季度或每年两次的维持剂量","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"1173012956","title":"Spyre Therapeutics：Spy003在所有剂量水平上耐受良好，安全性特征符合抗IL-23类药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1173012956","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173012956?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:40","pubTimestamp":1762292408,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics：Spy003在所有剂量水平上耐受良好，安全性特征符合抗IL-23类药物","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"1132251468","title":"Spyre Therapeutics发布Spy003的积极中期I期结果，这是一种新型半衰期延长的抗IL-23抗体","url":"https://stock-news.laohu8.com/highlight/detail?id=1132251468","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132251468?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:02","pubTimestamp":1762290128,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics发布Spy003的积极中期I期结果，这是一种新型半衰期延长的抗IL-23抗体","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"1188563637","title":"SPYRE THERAPEUTICS INC预计截至2025年9月30日现金及等价物为4.862亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188563637","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188563637?lang=zh_cn&edition=full","pubTime":"2025-10-14 18:27","pubTimestamp":1760437631,"startTime":"0","endTime":"0","summary":"SPYRE THERAPEUTICS INC预计截至2025年9月30日现金及等价物为4.862亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"1195222682","title":"Spyre Therapeutics宣布授予员工股票期权激励奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=1195222682","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195222682?lang=zh_cn&edition=full","pubTime":"2025-10-04 04:08","pubTimestamp":1759522131,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2025年10月3日——临床阶段生物技术公司Spyre Therapeutics, Inc.今日宣布，公司独立董事会薪酬委员会批准向三名非执行员工授予总计42,500股普通股的股票期权，作为根据经修订的《Spyre Therapeutics, Inc. 2018年股权激励计划》项下的股权激励奖励。Spyre Therapeutics是一家临床阶段生物技术公司，致力于通过结合一流的抗体工程、剂量优化和合理的治疗组合，开发下一代炎症性肠病和其他免疫介导疾病产品。Spyre的产品管线包括针对α4β7、TL1A和IL-23的研究性延长半衰期抗体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4539","NQmain","BK4139","IBD","SYRE"],"gpt_icon":0},{"id":"1123290538","title":"Spyre Therapeutics在开创性2期Skyway篮式试验中为首位患者给药，Spy072成为首个在风湿性疾病中研究的抗Tl1a抗体","url":"https://stock-news.laohu8.com/highlight/detail?id=1123290538","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123290538?lang=zh_cn&edition=full","pubTime":"2025-09-15 20:05","pubTimestamp":1757937901,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics在开创性2期Skyway篮式试验中为首位患者给药，Spy072成为首个在风湿性疾病中研究的抗Tl1a抗体","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2518327167","title":"Spyre Therapeutics, Inc.盘中异动 早盘股价大跌5.21%报18.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518327167","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518327167?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:36","pubTimestamp":1741617373,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时36分，Spyre Therapeutics, Inc.股票出现波动，股价大幅跳水5.21%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223613abf314b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223613abf314b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2518440864","title":"Spyre Therapeutics, Inc.2024财年实现净利润-1.50亿美元，同比减少58.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440864","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518440864?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449622,"startTime":"0","endTime":"0","summary":"3月9日，Spyre Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.50亿美元，同比减少58.09%；其中营业收入为0.00美元，每股基本收益为-3.18美元。从资产负债表来看，Spyre Therapeutics, Inc.总负债90.68百万美元，其中短期债务0.00美元，资产负债比为0.07，流动比率为0.12。机构评级：截至2025年3月9日，当前有8家机构对Spyre Therapeutics, Inc.目标价做出预测，其中目标均价为58.62美元，其中最低目标价为40.00美元，最高目标价为71.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000037abef96fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000037abef96fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","LENZ"],"gpt_icon":0},{"id":"1196051233","title":"异动解读 | Spyre Therapeutics Inc盘中大涨6.97%,新药研发取得重大进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1196051233","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196051233?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:08","pubTimestamp":1741187300,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc作为一家专注于新型肠病药物研发的生物技术公司,周三盘中出现了6.97%的大涨行情,引发了市场的广泛关注。分析人士指出,SYRE股价大涨的原因可能与该公司最新研发进展有关。SYRE的这款新药主打免疫调节作用,与现有主流药物采用不同的治疗机理,预计上市后将给这一疾病领域带来全新的治疗选择。随着临床数据的持续披露,投资者对新药未来前景的信心不断增强,这也是推动SYRE股价持续走高的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Spyre Therapeutics Inc盘中大涨6.97%,新药研发取得重大进展","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SYRE"],"gpt_icon":0},{"id":"2517943943","title":"Spyre Therapeutics, Inc.盘中异动 股价大涨6.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517943943","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517943943?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:32","pubTimestamp":1741185121,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时32分，Spyre Therapeutics, Inc.股票出现异动，股价快速拉升6.97%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223201963adc60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223201963adc60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2514781803","title":"Spyre Therapeutics, Inc.盘中异动 早盘快速上涨8.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514781803","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514781803?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753076,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Spyre Therapeutics, Inc.股票出现波动，股价快速拉升8.74%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223116a25800d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223116a25800d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SYRE","LENZ"],"gpt_icon":0},{"id":"2514516354","title":"Spyre Therapeutics(SYRE.US)：2024年Q4财报实现营收0美元，前值为0美元，预期值为233万美元；每股收益为-0.81美元，前值为-4.05美元，预期值为-0.97美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514516354","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514516354?lang=zh_cn&edition=full","pubTime":"2025-02-28 07:08","pubTimestamp":1740697720,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics(SYRE.US)：2024年Q4财报实现营收0美元，前值为0美元，预期值为233万美元；每股收益为-0.81美元，前值为-4.05美元，预期值为-0.97美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28070848442547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SYRE","LENZ"],"gpt_icon":0},{"id":"1141562432","title":"Spyre Therapeutics 2024年第四季度GAAP每股收益$(0.81) 优于$(1.01)的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1141562432","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141562432?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:46","pubTimestamp":1740692818,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics(LENZ) 2024年第四季度GAAP每股收益$(0.81)，优于$(1.01)的预期以上内容来自Benzinga Earnings专栏，原文如下：Spyre $Therapeutics(LENZ)$ Q4 2024 GAAP EPS $(0.81) Beats $(1.01) Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SYRE"],"gpt_icon":0},{"id":"2514861925","title":"Spyre Therapeutics, Inc.盘中异动 下午盘快速下跌5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514861925","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514861925?lang=zh_cn&edition=full","pubTime":"2025-02-27 03:14","pubTimestamp":1740597256,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日03时14分，Spyre Therapeutics, Inc.股票出现异动，股价急速下挫5.40%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.63%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227031417abde2ac4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227031417abde2ac4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","SYRE"],"gpt_icon":0},{"id":"2513029974","title":"Spyre Therapeutics, Inc.盘中异动 急速跳水5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513029974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513029974?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:03","pubTimestamp":1740150200,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日23时03分，Spyre Therapeutics, Inc.股票出现波动，股价大幅下跌5.00%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221230321962b8308&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221230321962b8308&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SYRE","BK4139"],"gpt_icon":0},{"id":"2512212196","title":"Spyre Therapeutics, Inc.盘中异动 大幅跳水5.24%报21.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512212196","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512212196?lang=zh_cn&edition=full","pubTime":"2025-02-19 03:20","pubTimestamp":1739906418,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日03时20分，Spyre Therapeutics, Inc.股票出现异动，股价快速下挫5.24%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.94%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219032018abd3ea20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219032018abd3ea20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SYRE","BK4139"],"gpt_icon":0},{"id":"2507969624","title":"Spyre Therapeutics, Inc.盘中异动 早盘急速上涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507969624","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507969624?lang=zh_cn&edition=full","pubTime":"2025-01-31 23:06","pubTimestamp":1738335969,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日23时06分，Spyre Therapeutics, Inc.股票出现异动，股价急速拉升5.07%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.07%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312306099614ef73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312306099614ef73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","SYRE"],"gpt_icon":0},{"id":"2506416303","title":"Spyre Therapeutics, Inc.盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506416303","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506416303?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:51","pubTimestamp":1737989486,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日22时51分，Spyre Therapeutics, Inc.股票出现异动，股价快速拉升5.00%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.11%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127225126a2316f11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127225126a2316f11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","SYRE"],"gpt_icon":0},{"id":"2505226271","title":"Spyre Therapeutics, Inc.盘中异动 早盘股价大涨5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505226271","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505226271?lang=zh_cn&edition=full","pubTime":"2025-01-21 22:34","pubTimestamp":1737470099,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日22时34分，Spyre Therapeutics, Inc.股票出现波动，股价快速拉升5.33%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.88%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121223459abb347af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121223459abb347af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","BK4139","LENZ"],"gpt_icon":0},{"id":"2503640475","title":"Spyre Therapeutics, Inc.盘中异动 急速拉升6.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503640475","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503640475?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:33","pubTimestamp":1736951604,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时33分，Spyre Therapeutics, Inc.股票出现异动，股价快速上涨6.51%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.84%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223324ababf2f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223324ababf2f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SYRE","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.spyre.com","stockEarnings":[{"period":"1week","weight":0.0982},{"period":"1month","weight":0.1311},{"period":"3month","weight":0.5595},{"period":"6month","weight":1.3166},{"period":"1year","weight":0.4719},{"period":"ytd","weight":0.072}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Spyre Therapeutics, Inc.于2013年12月16日从特拉华州有限责任公司转换而来。该公司是一家生物技术公司，旨在通过结合同类最佳的抗体工程、合理的治疗组合以及用于患者选择的精准医疗方法，创造下一代炎症性肠病（IBD）产品。Spyre的产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.035303},{"month":2,"riseRate":0.5,"avgChangeRate":0.00424},{"month":3,"riseRate":0.444444,"avgChangeRate":0.005514},{"month":4,"riseRate":0.111111,"avgChangeRate":-0.063951},{"month":5,"riseRate":0.5,"avgChangeRate":-0.058711},{"month":6,"riseRate":0.4,"avgChangeRate":0.119173},{"month":7,"riseRate":0.4,"avgChangeRate":-0.002229},{"month":8,"riseRate":0.8,"avgChangeRate":0.108946},{"month":9,"riseRate":0.6,"avgChangeRate":0.016514},{"month":10,"riseRate":0.4,"avgChangeRate":0.109394},{"month":11,"riseRate":0.4,"avgChangeRate":0.005048},{"month":12,"riseRate":0.4,"avgChangeRate":-0.019416}],"exchange":"NASDAQ","name":"SPYRE THERAPEUTICS INC","nameEN":"SPYRE THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供SPYRE THERAPEUTICS INC(SYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"SPYRE THERAPEUTICS INC,SYRE,SPYRE THERAPEUTICS INC股票,SPYRE THERAPEUTICS INC股票老虎,SPYRE THERAPEUTICS INC股票老虎国际,SPYRE THERAPEUTICS INC行情,SPYRE THERAPEUTICS INC股票行情,SPYRE THERAPEUTICS INC股价,SPYRE THERAPEUTICS INC股市,SPYRE THERAPEUTICS INC股票价格,SPYRE THERAPEUTICS INC股票交易,SPYRE THERAPEUTICS INC股票购买,SPYRE THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供SPYRE THERAPEUTICS INC(SYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}